Long-term follow-up in the PALLAS study showed no overall survival benefit with palbociclib plus endocrine therapy compared to endocrine therapy alone in hormone receptor-positive, HER2-negative ...

First-of-its-kind comparative analysis of real-world data in the CDK 4/6 inhibitor class supports benefits of IBRANCE combination therapy initially shown in clinical trials Among the data, Pfizer will ...

NEW YORK--(BUSINESS WIRE)-- As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. (NYSE: PFE) reports that following a ...

IBRANCE is an oral inhibitor of CDKs 4 and 6, 1 which are key regulators of the cell cycle that trigger cellular progression. 2,3 In the U.S., IBRANCE is indicated for the treatment of HR+, HER2- ...

Pfizer Announces PALOMA-3 Trial For IBRANCE® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine ...

The nation's largest drug-maker is throwing a victory party right now. One of the most anticipated drugs in Pfizer's (NYSE:PFE) pipeline just got a crucial FDA approval. The drug, (palbociclib, but ...

Those were the findings of the phase 3 PALOMA-3 trial, presented May 30 during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of nearly 30,000 oncology ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the peer-reviewed publication of real-world evidence (RWE) demonstrating that first-line therapy with IBRANCE® (palbociclib) in ...

The U.S. Food and Drug Administration (FDA) has agreed to review a supplemental New Drug Application (sNDA) of CDK 4/6 inhibitor, IBRANCE (palbociclib) from Pfizer Inc. (NYSE:PFE). The sNDA was ...

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE ® (palbociclib) 125mg capsules, Pfizer’s metastatic ...

First Cyclin-Dependent Kinase 4/6 (CDK 4/6) Inhibitor Approved by the FDA IBRANCE Now Available for Use in Combination with Letrozole as First-Line Treatment of Postmenopausal Women with Estrogen ...